Basket cover image
16 handpicked stocks

Trust In Numbers: The Private Data Advantage

The firing of the U.S. Labor Statistics chief has undermined trust in the integrity of government economic reporting. This creates a potential shift towards private data and analytics firms as more reliable sources of crucial market information.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+6

Author avatar

Han Tan | Market Analyst

Updated today | Published at Aug 3

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

FICO

Fair Isaac Corp

FICO

Current price

$1,360.99

VRSK

Verisk Analytics, Inc.

VRSK

Current price

$268.00

MORN

Morningstar Inc.

MORN

Current price

$270.40

About This Group of Stocks

1

Our Expert Thinking

Recent events have shaken confidence in government economic data, creating a potential shift towards private sector alternatives. This group focuses on companies that provide independent data analytics, credit reporting, and financial information services that operate outside government influence.

2

What You Need to Know

These are established data and analytics companies that serve financial markets with proprietary information. They offer alternative sources of economic insights that could become increasingly valuable as market participants seek unbiased, reliable data for decision-making.

3

Why These Stocks

Each company was handpicked by professional analysts for their role in providing independent financial data and analytics services. They represent a tactical play on the growing importance of trusted, non-governmental data sources in financial markets.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+21.16%

Group Performance Snapshot

21.16%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 21.16% over the next year.

12 of 16

Stocks Rated Buy by Analysts

12 of 16 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🔍

Trust Crisis Creates Opportunity

When confidence in government data wavers, smart money turns to private alternatives. These companies could see increased demand as markets seek reliable, independent information sources.

📊

Data Is The New Gold

In an era of information uncertainty, companies that provide trusted analytics and financial data become increasingly valuable. These firms hold the keys to market intelligence that investors desperately need.

First-Mover Advantage

This shift towards private data providers is happening right now. Getting positioned early in this trend could put you ahead of the curve as demand for independent market intelligence grows.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Unlock all the stocks in this group on Nemo

Sign up free to view all stocks in this group and never miss out on another investment opportunity with Nemo.

Sign up to Nemo FREE
At least 12 characters
Contains letters and numbers

By signing up you are agreeing to NemoMoney's T&C's

Sign up in 60 seconds

🆓

Zero commission trading

🛡️

SIPC-protected up to $500,000

🔒

Backed by Exinity Group

🚀

6% AER interest on uninvested cash, paid out daily

AI investment insights

Discover More Opportunities

Beyond Vaccines: The mRNA Revolution

Beyond Vaccines: The mRNA Revolution

BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.

View stocks
Navigating U.S. Drug Price Reforms

Navigating U.S. Drug Price Reforms

The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.

View stocks
Aerospace Rivals In Focus Amid Labor Unrest

Aerospace Rivals In Focus Amid Labor Unrest

A significant strike by Boeing's defense workers in St. Louis is set to disrupt the production of crucial military aircraft. This development could create a strategic advantage for competing aerospace and defense firms poised to capture market share.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.